IBRX FY 2023 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena

IBRXImmunityBio, Inc.

$8B

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$622,000+159.2% YoY

Gross Profit

$622,000100.0% margin

Operating Income

-$362M-58239.5% margin

Net Income

-$583M-93761.4% margin

EPS (Diluted)

$-1.15

Cash Flow

Operating Cash Flow

-$367M

Free Cash Flow

-$397M

Stock-Based Comp.

$49M

Balance Sheet

Total Assets

$504M

Total Liabilities

$1.1B

Stockholders' Equity

-$587M

Cash & Equivalents

$265M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$622,000	$240,000	+159.2%
Gross Profit	$622,000	$240,000	+159.2%
Operating Income	-$362M	-$351M	-3.1%
Net Income	-$583M	-$417M	-40.0%